Early Phase Clinical Research Support

早期临床研究支持

基本信息

项目摘要

The St. Jude Comprehensive Cancer Center (SJCCC) leadership views the design and implementation of investigator-initiated clinical trials as a top priority. This activity is especially valued when it translates discoveries made in SJCCC basic research laboratories to novel therapies that promise to improve the survival of children with cancer. The EPCRS provides an important mechanism of support this work enabling investigators to conduct high-priority translational studies that are not typically supported by other funding mechanisms. The EPCRS supports clinical research nurses (CRA-RNs) and clinical research associates (CRAs) dedicated to the conduct and completion of these innovative pilot and Phase I investigator-initiated trials within the SJCCC. Clinical research personnel supported by the EPCRS help manage and ensure the success of these protocols by providing a broad range of services including: maintaining protocol-specific research data; ensuring protocol compliance; preparing progress and safety reports; coordinating of specimen collection and compliance with the numerous biological and pharmacological endpoints; and coordinating the abstraction and assimilation of necessary data for analyses and reporting. Many of our EPCRS supported protocols involve an IND or IDE and/or novel agents developed within the SJCCC; thus, additional regulatory functions are required. Candidate trials for EPCRS are first identified within the SJCCC Programs and reviewed and approved by the SJCCC Director and the Associate Director for Clinical Research, who also provide budget oversight. Funding is requested for an appropriate portion of salary support for clinical research nurses, clinical research associates (CRAs), and study coordinators for work supporting EPCRS-eligible trials.
圣裘德综合癌症中心(SJCCC)的领导层将设计和实施研究人员发起的临床试验视为重中之重。当这项活动将SJCCC基础研究实验室的发现转化为有望提高癌症儿童存活率的新疗法时,这项活动尤其有价值。EPCRS提供了支持这项工作的重要机制,使调查人员能够进行通常不受其他供资机制支持的高度优先的转化性研究。EPCRS支持临床研究护士(CRA-RN)和临床研究助理(CRA),他们致力于在SJCCC内进行和完成这些创新的试点和第一阶段研究人员发起的试验。在EPCRS的支持下,临床研究人员通过提供广泛的服务来帮助管理和确保这些方案的成功,这些服务包括:维护方案特定的研究数据;确保方案的遵从性;编写进展和安全报告;协调标本收集并遵守众多生物和药物终点;以及协调分析和报告所需数据的提取和同化。我们支持的许多EPCRS协议涉及IND或IDE和/或在SJCCC内开发的新型代理;因此,需要额外的监管功能。EPCR的候选试验首先在SJCCC计划中确定,并由SJCCC主任和临床研究副主任审查和批准,他们还提供预算监督。为临床研究护士、临床研究助理(CRA)和研究协调员支持符合EPCRS资格的试验的工作提供适当部分的工资支持,要求提供资金。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard James Gilbertson其他文献

Richard James Gilbertson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard James Gilbertson', 18)}}的其他基金

Shared Resource Group 3: Advanced Laboratory Technologies
共享资源组 3:先进实验室技术
  • 批准号:
    8637117
  • 财政年份:
    2014
  • 资助金额:
    $ 25.62万
  • 项目类别:
Molecular Clinical Trials Core (MCTC) Share Resource
分子临床试验核心 (MCTC) 共享资源
  • 批准号:
    8738019
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Development
发展
  • 批准号:
    8738017
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8738016
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Senior Leadership
高层领导
  • 批准号:
    8738014
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Program Leaders
项目负责人
  • 批准号:
    8738015
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Administration
行政
  • 批准号:
    8738022
  • 财政年份:
    2012
  • 资助金额:
    $ 25.62万
  • 项目类别:
Molecular Clinical Trians
分子临床试验
  • 批准号:
    7714162
  • 财政年份:
    2008
  • 资助金额:
    $ 25.62万
  • 项目类别:
An investigation of radial glia as the source of ependymoma stem cells
放射状胶质细胞作为室管膜瘤干细胞来源的研究
  • 批准号:
    7624659
  • 财政年份:
    2007
  • 资助金额:
    $ 25.62万
  • 项目类别:
An investigation of radial glia as the source of ependymoma stem cells
放射状胶质细胞作为室管膜瘤干细胞来源的研究
  • 批准号:
    8073588
  • 财政年份:
    2007
  • 资助金额:
    $ 25.62万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 25.62万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 25.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了